KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Net Income towards Common Stockholders (2016 - 2026)

Abbott Laboratories' Net Income towards Common Stockholders history spans 18 years, with the latest figure at $1.1 billion for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 18.72% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.3 billion, a 53.52% decrease, with the full-year FY2025 number at $6.5 billion, down 51.32% from a year prior.
  • Net Income towards Common Stockholders hit $1.1 billion in Q1 2026 for Abbott Laboratories, down from $1.8 billion in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ABT hit a ceiling of $9.2 billion in Q4 2024 and a floor of $1.0 billion in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged $2.0 billion across 5 years, with a median of $1.4 billion in 2023.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 478.98% in 2024 and later crashed 80.76% in 2025.
  • Tracing ABT's Net Income towards Common Stockholders over 5 years: stood at $1.0 billion in 2022, then surged by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then crashed by 80.76% to $1.8 billion in 2025, then crashed by 39.36% to $1.1 billion in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for ABT at $1.1 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.6 billion in Q3 2025.